Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia - PubMed
4 days ago
- #B-ALL
- #Cost-effectiveness
- #Blinatumomab
- Study evaluates cost-effectiveness of blinatumomab for MRD-negative, Ph-negative B-ALL in adults.
- Markov model compares blinatumomab alternating with chemotherapy vs. standard chemotherapy in Japan and the US.
- In Japan, ICER was ¥7,193,601 per QALY; in the US, ICER was $134,298 per QALY.
- Blinatumomab cost-effective if 3-year PFS is ≥80%, unless SOC PFS exceeds 64.9% (Japan) or 65.6% (US).
- Less cost-effective for patients older than 51.6 years (Japan) and 55.6 years (US).
- Blinatumomab is cost-effective as consolidation therapy, sensitive to age and PFS gains.